Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neurobiological Correlates of Duloxetine in MDD
NCT01051466Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2010
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of duloxetine in major depressive disorder (MDD) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change From Baseline to 12-Week Endpoint in the Functional Magnetic Resonance Imaging (fMRI) Mean Blood Oxygenation-Level-Dependent (BOLD) Response in the Amygdalae. Started Jan 2010; status: completed.
02
Drugs
duloxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01051466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01051466.